

Research Article

The effect of 12 weeks of aerobic exercise intervention on bone mineral density, expression of lymphocyte alkaline phosphatase gene and bone turnover markers in overweight postmenopausal women: a randomized controlled trial

Abbas Malandish^{1*}, Zeinab Sheikhlou^{2*}, Bakhtyar Tartibian³, Mohammad Rahmati-Yamchi⁴

Abstract

The aim of our study was to examine the effect of 12 weeks of moderate-intensity aerobic exercise on bone mineral density (BMD), lymphocyte alkaline phosphatase (ALP) mRNA expression, and biochemical markers of bone turnover in postmenopausal women (PMWs). Twenty-four healthy sedentary PMWs aged 50-60 years were randomly assigned to exercise (EX, n=12) and control (C, n=12) groups. The EX group performed walking/jogging (50-60min/day, 3days/week at 65%-70% HRmax reserve) for 12-week while the C group participated in no intervention and continued their normal lifestyle. The BMD and lymphocyte ALP mRNA were determined by DXA and gRT-PCR, respectively. After 12 weeks, the increase in the lymphocyte ALP mRNA expression and its serum (P=0.008 and P=0.001), PTH (P=0.001), Vit-D (P=0.002), and VO2max (P=0.001) were significantly higher in the EX group compared to the C group, whereas body fat was significantly decreased (P=0.028). Our study indicates that 12 weeks of moderate-intensity aerobic exercise intervention improves bone turnover by increasing the ALP mRNA expression, serum levels of PTH, ALP, and Vit-D which can lead to the prevention of aging-induced osteopenia among PMWs.

Key Words: Aerobic exercise, Bone, Alkaline phosphatase, Menopause, Bone turnover

A M: 0000-0002-3061-4172; Z Sh: 0000-0001-7343-7471; B T: 0000-0002-4653-5620; M R-Y: 0000-0001-7791-3287

Introduction

Menopause status is related to changes in sex hormones (Khalafi et al., 2021; Malandish et al., 2020a; Malandish et al., 2020b; Tartibian et al., 2017) as well as bone disorders (Malandish et al., 2016; Sheikhlou et al., 2016). Bone loss and osteoporosis among postmenopausal women (PMWs) have been identified as a global health problem (Eastell et al., 2019; Edwards, 2017), and fractures resulting from these defects are the main causes of mortality in older people (Cauley et al., 2012; Eastell et al., 2019). Also, sedentary-induced disorders are other factors that affect osteoporosis. Besides the genetic and environmental factors affecting bone mineral density (BMD) (Stewart & Ralston, 2000), aerobic exercise and cellularmolecular mechanisms are also involved in BMD (Tartibian, Hajizadeh Maleki, Kanaley, & Sadeghi, 2011; Yu et al., 2019). It seems that a reduction in estrogen and progesterone after menopause in women leads to disturbances in bone metabolism regulation systems such as skeletal (Azadpour, Tartibian, & KoSar, 2016; Karinkanta, 2017; Malandish et al., 2016; Tartibian, Hajizadeh Maleki, Kanaley, & Sadeghi, 2011) and cardiovascular systems (CVS) (Azadpour, Tartibian, & Koşar, 2016). The aerobic exercise is an important nonmedication factor in old women to take care of their health and BMD later in life span (Karinkanta, 2017; Tartibian, Hajizadeh Maleki, Kanaley, & Sadeghi, 2011). In other words, moderate intensity aerobic exercise intervention is one of the most effective ways of reducing risk factors of bone loss and/or osteoporosis and mortality (Malandish et al., 2016; Tartibian et al., 2018a; Tartibian et al., 2018b; Tartibian, Hajizadeh Maleki, Kanaley, & Sadeghi, 2011). However, the role of gene expression and cell signaling cascades are not fully understood in BMD and bone metabolism following aerobic exercise intervention and there are currently no studies regarding the association between the human ALP gene expression and exercise in scientific databases. Interestingly, several studies have examined the effects of exercise on serum markers of bone metabolism and BMD, but their results are completely co-

^{1.} Aff 1: Ph.D of Exercise Physiology, Department of Exercise Physiology, Faculty of Sport Sciences, Urmia University, Urmia, Iran. Aff2: Head of Exercise Physiology Clinic, Urmia, Iran. 2. MSc of Exercise Physiology, Department of Exercise Physiology, Faculty of Sport Sciences, Urmia University, Urmia, Iran. 3. Full Professor of Exercise Physiology, Department of Sport Injuries & Corrective Exercises, Faculty of Sport Sciences, Allameh Tabataba'i University, Tehran, Iran. 4. Full Professor of Clinical Biochemistry, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

^{*}Authors for correspondence: malandish@gmail.com & z.sheikhlou@gmail.com

-ntradictory. Therefore, the first purpose of this study was to examine the effect of 12 weeks of moderate-intensity aerobic exercise on BMD in PMWs. Also, an attempt was made to examine the effect of 12 weeks of moderate-intensity aerobic exercise on lymphocyte ALP gene expression and BMD. The third purpose was to determine the changes in serum levels of bone markers following moderate-intensity aerobic exercise intervention. In addition, estimating the correlations between BMD and ALP gene expression with serum levels of bone markers and other variables of this study were the fourth purpose of our study.

Materials and Methods

Healthy sedentary PMWs as participants

This study was performed in a randomized control design. All stages of this study were approved by the Ethics Committee of medical-biological sciences at Urmia University of medical sciences with code ir.umsu.rec.1394.453 and were conducted in September 2017 at Urmia University, Iran. During the public notice of exercise and PMWs, 100 healthy and sedentary PMWs were selected, out of 100 PMWs recruited into the study, 50 participants obtained initial conditions. Finally, after evaluating BMD by using Dual-energy X-ray Absorptiometry (DXA-HOLOGIC®, USA), 26 participants were eliminated due to osteopenia/osteoporosis and 24 human volunteers as participants met the inclusion criteria for the study (of the 76 participants excluded, 25 PMWs had hypertension, 20 PMWs pharmacological interventions. 5 **PMWs** had had electrocardiogram abnormalities, and 26 PMWs had BMD disorders based on T score values including osteopenia and osteoporosis). The inclusion criteria of healthy sedentary PMWs as participants included: (1) PMWs with the age range of 50 to 60 years spending at least 1 year and/or less than 5 years at menopause, as this was controlled by evaluating the normal menopause serum levels of 17β -estradiol (11-65 μ L/pg) and progesterone (0.1-1 µL/ng); (2) No history of bone fractures or current diseases affecting bone metabolism as well as any clinical problem in the skeletal system and CVS; (3) No history of regular exercise, weight gain, weight loss, smoking and medications for at least 6 months before the start of the study; and (4) having normal BMD values at the whole body, lumbar spine (L1-L4), and femoral neck. Bone mass was measured by using DXA based on the world health organization (WHO) definition from normal BMD or T score values (Normal>-1SD; -2.5SD<Osteopenia≤-1SD; and Osteoporosis≤2.5SD). The CVS was evaluated based on the normal electrocardiogram (ECG) (Esaote Spa, Firenze, Italy). Exclusion criteria of human volunteers as participants included: (1) Identification and diagnosis of chronic diseases affecting bone metabolism as well

as any medical disease during 12-week; (2) Discontinue of regular exercise protocol during 12 weeks; and (3) dietary regimen, weight gain, weight loss, and any pharmacological treatment during 12 weeks. Physical activity level of PMWs was measured by physical activity assessment (PAA) method (Strath

Table 1: Physiological characteristics, menopause status, and bone parameters of PMWs at baseline and week 12 in the EX and C groups.

			_		
Variables	EX (n=12)	C (n=12)	P ^b value	P ^c value	Eta
					coefficient
Physiological characte	eristics				(%)
Age (yr)	11000				
Baseline	53.36±3.98	53.00±3.26	ns	ns	ns
Week 12	53.36±3.98	53.00±3.26	ns	•	
Pª value	ns	ns			
Height (cm)					
Baseline	157.45±45	158.40±5.42	ns	ns	ns
Week 12	-	-	ns	•	
Pª value	ns	ns			
Weight (kg)					
Baseline	73.18±10.30	74.72±14.10	0.706	0.329	0.050 (5%)
Week 12	72.72±10.11	77.27±15.98	0.484		
Pª value	0.526	0.199			
Body mass index (kg	J/m²)				
Baseline	30.26±4.91	29.58±5.35	0.759	0.053	0.183
Week 12	29.67±5.17	30.68±6.34	0.688		(18.3%)
P⁴ value	0.185	0.157			
Total body fat (%)					
Baseline	42.03±5.10	40.54±5.50	0.914	±0.028	0.228
Week 12	41.15±4.87	41.45±5.55	0.898		(22.8%)
Pª value	'0.023	0.188			
Systolic blood press	. •	440.05 -5-55	0.751		
Baseline	120.45±16.37	116.80±17.66	0.484	0.714	0.119
Week 12	111.63±20.08	123.20±14.30	0.841		(11.9%)
Pª value	0.373	0.088			
Diastolic blood press					
Baseline	75.18±8.85	79.00±13.82	0.456	0.490	0.001 (0.1%)
Week 12	76.81±5.91	80.70±10.49	0.304		
Pª value	0.603	0.355			
Resting heart rate (be		70 70 40 70	0.400	0.470	0.004 (0.40)
Baseline	80.81±10.94	76.72±10.70	0.186	0.472	0.031 (3.1%)
Week 12	78.54±6.81	76.27±9.23	0.287		
Pa value	0.307	0.657			
VO₂max (ml/kg/min)	39.05±2.25	40.03±5.74	0.713	‡0.001	0.534
Baseline Week 42	43.56±2.13	39.26±6.41	0.713	0.001	(53.4%)
Week 12 P ^a value	*0.001	0.132	0.174		(00.7/0)
Walking & Jogging ti Baseline	9.93±2.62	9.77±2.76	0.894	‡0.001	0.551
Week 12	12.16±1.97	9.62±2.61	10.027	0.001	(55.1%)
Pa value	*0.001	0.468	10.021		\
Metabolic equivalent					
Baseline	11.60±0.81	12.00±1.13	0.349		
Week 12	14.93±1.00	11.89±1.13	†0.001	‡0.001	0.979
			1		(97.9%)
Pª value	*0.001	0.187			1
Menopause status					
Menopause age (yr)					
Baseline	3.18±1.25	2.62±1.18	0.342	ns	ns
Week 12	3.18±1.25	2.62±1.18	0.342	•	
Pª value	ns	ns			

Cambianca	of table	4
Continue	of table :	1

P* value						
Week 12	17β-estradio	l (ng/μl)				
P* value	Baseline	31.53±16.28	41.06±12.65	0.202	0.123	0.117
Progesterone (ng/µl)	Week 12	29.73±15.36	23.85±12.30	0.402	•	(11.7%)
Baseline	Pª value	0.693	*0.031			
Week 12	Progesterone	(ng/µl)				
Week 12	Baseline	0.18±0.10	0.30±0.14	0.084	0.495	0.026 (2.6%)
Bone parameters	Week 12	0.14±0.07	0.20±0.17	0.401	•	
BMD total whole body (g/cm²) Baseline 1.02±0.07 1.000±0.08 0.523 0.475 0.029 (2.9² Week 12 1.02±0.07 0.981±0.12 0.368	Pª value	0.104	*0.033			
Baseline 1.022±0.07 1.000±0.08 0.523 0.475 0.029 (2.99 1.002±0.07 0.981±0.12 0.368 0.368 0.475 0.029 (2.99 1.002±0.07 0.981±0.12 0.368 0.368 0.475 0.029 (2.99 1.002±0.07 0.9952 0.390 0.382 0.048 (4.89 1.002±0.01 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.14 0.660 0.984 0.884 0.8853 0.880 0.884 0.8853 0.880 0.884 0.8853 0.880 0.880 0.884 0.8853 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880	Bone paramet	ers				
Baseline 1.022±0.07 1.000±0.08 0.523 0.475 0.029 (2.99 1.002±0.07 0.981±0.12 0.368 0.368 0.475 0.029 (2.99 1.002±0.07 0.981±0.12 0.368 0.368 0.475 0.029 (2.99 1.002±0.07 0.9952 0.390 0.382 0.048 (4.89 1.002±0.01 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.13 0.672 0.904±0.14 0.660 0.984 0.884 0.8853 0.880 0.884 0.8853 0.880 0.884 0.8853 0.880 0.880 0.884 0.8853 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880 0.880	BMD total wh	ole body (a/cm²)				
P' value			1.000±0.08	0.523	0.475	0.029 (2.9%)
BMD L1 (g/cm²) Baseline	Week 12	1.022±0.07	0.981±0.12	0.368	•	, ,
BMD L1 (g/cm²) Baseline	Pª value	0.952	0.390			
Baseline						
Week 12 0.929±0.12 0.904±0.13 0.672 P* value 0.208 0.113 BMD L2 (g/cm²) Baseline 1.069±0.10 1.026±0.10 0.381 0.256 0.080 (8%) Week 12 1.044±0.10 1.023±0.11 0.660 0.660 0.081 (8%) P* value 0.084 0.853 0.660 0.0679 0.011 (1.19) Baseline 1.091±0.11 1.050±0.10 0.441 0.679 0.011 (1.19) Week 12 1.072±0.12 1.024±0.09 0.365 0.679 0.011 (1.19) Baseline 1.084±0.11 1.074±0.11 0.854 0.264 0.077 (7.79) Baseline 1.084±0.11 1.074±0.11 0.854 0.264 0.077 (7.79) Week 12 1.088±0.10 1.060±0.13 0.587 0.264 0.077 (7.79) Baseline 1.045±0.10 1.012±0.09 0.501 0.775 0.005 (0.50) Week 12 1.039±0.11 1.00±0.10 0.538 0.256 0.053 (5.30) P* value <th< th=""><th></th><th>•</th><th>0.865+0.11</th><th>0 418</th><th>0.382</th><th>0 048 (4 8%)</th></th<>		•	0.865+0.11	0 418	0.382	0 048 (4 8%)
P' value 0.208 0.113					•	0.0.10 (1.070)
BMD L2 (g/cm²) Baseline						
Baseline			0.110			
Week 12 1.044±0.10 1.023±0.11 0.660 P* value 0.084 0.853 BMD L3 (g/cm²) Baseline 1.091±0.11 1.050±0.10 0.441 0.679 0.011 (1.19) Week 12 1.07±0.12 1.024±0.09 0.365 0.365 0.071 BMD L4 (g/cm²) Baseline 1.084±0.11 1.074±0.11 0.854 0.264 0.077 (7.79) Week 12 1.088±0.10 1.060±0.13 0.587 0.264 0.077 (7.79) Baseline 1.08±0.10 1.060±0.13 0.587 0.264 0.077 (7.79) Baseline 1.045±0.10 1.012±0.09 0.501 0.775 0.005 (0.59) Week 12 1.039±0.11 1.00±0.10 0.538 0.356 0.053 (5.39) P* value 0.515 0.710 0.0710 0.079 (7.99) 0.0710 0.079 (7.99) Baseline 0.779±0.04 0.829±0.09 0.328 0.231 0.079 (7.99) P* value 0.422 0.999 0.079 (7.99) 0.079 (7.99) 0.079 (7.99			1 026+0 10	0.381	0.256	0.080 (8%)
P* value					. 0.200	0.000 (070)
BMD L3 (g/cm²) Baseline 1.091±0.11 1.050±0.10 0.441 0.679 0.011 (1.19) Week 12 1.072±0.12 1.024±0.09 0.365 P* value 0.317 0.071 BMD L4 (g/cm²) Baseline 1.084±0.11 1.074±0.11 0.854 0.264 0.077 (7.79) Week 12 1.088±0.10 1.060±0.13 0.587 P* value 0.692 0.289 BMD Total lumbar vertebral (g/cm²) Baseline 1.045±0.10 1.012±0.09 0.501 0.775 0.005 (0.59) Week 12 1.039±0.11 1.00±0.10 0.538 P* value 0.515 0.710 BMD Femoral neck (g/cm²) Baseline 0.779±0.04 0.829±0.10 0.188 0.356 0.053 (5.39) Week 12 0.773±0.04 0.829±0.09 0.328 P* value 0.422 0.999 T score Total whole body Baseline -0.918±0.80 -0.960±0.60 0.895 0.231 0.079 (7.99) Week 12 -0.909±0.90 -1.200±0.92 .0475 P* value 0.884 0.247 T score Total lumbar vertebral (L1-L4) Baseline 1.045±0.10 1.012±0.09 0.474 0.676 0.011 (1.19) Week 12 1.039±0.11 1.00±0.10 0.560 P* value 0.515 0.710 T score Femoral neck Baseline -0.618±0.41 -0.187±0.97 0.205 0.785 0.005 (0.59)				0.000		
Baseline			0.000			
Week 12 1.072±0.12 1.024±0.09 0.365 P* value 0.317 0.071 BMD L4 (g/cm²) Baseline 1.084±0.11 1.074±0.11 0.854 0.264 0.077 (7.7° Week 12 1.088±0.10 1.060±0.13 0.587 0.264 0.077 (7.7° P* value 0.692 0.289 0.289 0.587 0.005 (0.5° BmD Total lumbar vertebral (g/cm²) 0.289 0.501 0.775 0.005 (0.5° Week 12 1.045±0.10 1.012±0.09 0.501 0.775 0.005 (0.5° Baseline 0.515 0.710 0.710 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.		•	1.050+0.10	0.441	0.670	0.011 (1.19/)
P* value 0.317 0.071 BMD L4 (g/cm²) Baseline 1.084±0.11 1.074±0.11 0.854 0.264 0.077 (7.7° Week 12 1.088±0.10 1.060±0.13 0.587 0.587 0.077 (7.7° P* value 0.692 0.289 0.289 0.051 0.775 0.005 (0.5° BmD Total lumbar vertebral (g/cm²) 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.005 (0.5° 0.0					0.079	0.011 (1.1%)
BMD L4 (g/cm²) Baseline				0.303		
Baseline			0.071			
Week 12 1.088±0.10 1.060±0.13 0.587 P* value 0.692 0.289 BMD Total lumbar vertebral (g/cm²) Baseline 1.045±0.10 1.012±0.09 0.501 0.775 0.005 (0.5° Week 12 1.039±0.11 1.00±0.10 0.538 P** value 0.515 0.710 BMD Femoral neck (g/cm²) Baseline 0.779±0.04 0.829±0.10 0.188 0.356 0.053 (5.3° Week 12 0.773±0.04 0.829±0.09 0.328 0.356 0.053 (5.3° P* value 0.422 0.999 0.328 0.231 0.079 (7.9° Baseline -0.918±0.80 -0.960±0.60 0.895 0.231 0.079 (7.9° Week 12 -0.909±0.90 -1.200±0.92 .0475 0.231 0.079 (7.9° P* value 0.884 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 <th></th> <th>•</th> <th>4.074.0.44</th> <th>0.054</th> <th>0.004</th> <th>0.077 (7.70()</th>		•	4.074.0.44	0.054	0.004	0.077 (7.70()
P³ value 0.692 0.289 BMD Total lumbar vertebral (g/cm²) Baseline 1.045±0.10 1.012±0.09 0.501 0.775 0.005 (0.5° Week 12 1.039±0.11 1.00±0.10 0.538 P³ value 0.515 0.710 BMD Femoral neck (g/cm²) Baseline 0.779±0.04 0.829±0.10 0.188 0.356 0.053 (5.3° Week 12 0.773±0.04 0.829±0.09 0.328 0.356 0.053 (5.3° P³ value 0.422 0.999 0.328 0.231 0.079 (7.9° Baseline -0.918±0.80 -0.960±0.60 0.895 0.231 0.079 (7.9° Week 12 -0.909±0.90 -1.200±0.92 0.475 0.231 0.079 (7.9° P³ value 0.884 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247 0.247					0.204	0.077 (7.7%)
BMD Total lumbar vertebral (g/cm²) Baseline				0.567		
Baseline			0.209			
Week 12 1.039±0.11 1.00±0.10 0.538 P* value 0.515 0.710 BMD Femoral neck (g/cm²) 0.779±0.04 0.829±0.10 0.188 0.356 0.053 (5.3°) Week 12 0.773±0.04 0.829±0.09 0.328 0.356 0.053 (5.3°) 0.053 (5.3°) P* value 0.422 0.999 0.328 0.356 0.053 (5.3°) Baseline -0.918±0.80 -0.960±0.60 0.895 0.231 0.079 (7.9°) Week 12 -0.909±0.90 -1.200±0.92 .0475 0.0475 0.079 (7.9°) P* value 0.884 0.247 0.247 0.075 0.076 0.011 (1.1°) Baseline 1.045±0.10 1.012±0.09 0.474 0.676 0.011 (1.1°) Week 12 1.039±0.11 1.00±0.10 0.560 0.0560 0.0560 P* value 0.515 0.710 0.785 0.005 (0.5°) T score Femoral neck 0.018±0.41 -0.187±0.97 0.205 0.785 0.005 (0.5°)			1 012±0 00	0.501	0.775	0.005 (0.5%)
P³ value 0.515 0.710 BMD Femoral neck (g/cm²) Baseline 0.779±0.04 0.829±0.10 0.188 0.356 0.053 (5.3° Week 12 0.773±0.04 0.829±0.09 0.328 0.356 0.053 (5.3° P³ value 0.422 0.999 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.321 0.079 (7.99 0.328 0.321					- 0.110	0.000 (0.070)
BMD Femoral neck (g/cm²)				0.000		
Baseline 0.779±0.04 0.829±0.10 0.188 0.356 0.053 (5.3°) Week 12 0.773±0.04 0.829±0.09 0.328 P* value 0.422 0.999 0.999 T score Total whole body 0.828 0.895 0.231 0.079 (7.9°) Week 12 -0.909±0.90 -1.200±0.92 .0475 0.231 0.079 (7.9°) P* value 0.884 0.247 0.247 0.247 0.676 0.011 (1.1°) Baseline 1.045±0.10 1.012±0.09 0.474 0.676 0.011 (1.1°) Week 12 1.039±0.11 1.00±0.10 0.560 0.560 0.011 (1.1°) T score Femoral neck Baseline -0.618±0.41 -0.187±0.97 0.205 0.785 0.005 (0.5°)			0.710			
Week 12 0.773±0.04 0.829±0.09 0.328 P* value 0.422 0.999 T score Total whole body Baseline -0.918±0.80 -0.960±0.60 0.895 0.231 0.079 (7.9°) Week 12 -0.909±0.90 -1.200±0.92 .0475 -0.475 -0.247 -0.247 -0.247 -0.247 -0.247 -0.676 0.011 (1.1°) -0.676 0.011 (1.1°) -0.676 0.011 (1.1°) -0.676 0.011 (1.1°) -0.676 0.011 (1.1°) -0.560 -0.560 -0.576 0.011 (1.1°) -0.560 -0.576 0.011 (1.1°) -0.560 -0.576 0.011 (1.1°) -0.560 -0.576 0.011 (1.1°) -0.560 -0.576 0.011 (1.1°) -0.560 -0.576 0.011 (1.1°) -0.576 0.011 (1.1°) -0.576 0.011 (1.1°) -0.576 0.011 (1.1°) -0.576 0.011 (1.1°) -0.576 0.011 (1.1°) -0.576 0.011 (1.1°) -0.576 0.011 (1.1°) -0.576 0.011 (1.1°) -0.576 0.011 (1.1°) -0.576 0.011 (1.1°) -0.57			0.829+0.10	0.188	0.356	0.053 (5.3%)
P* value 0.422 0.999 T score Total whole body Baseline -0.918±0.80 -0.960±0.60 0.895 0.231 0.079 (7.9° Week 12 -0.909±0.90 -1.200±0.92 .0475 P* value 0.884 0.247 T score Total lumbar vertebral (L1-L4) Baseline 1.045±0.10 1.012±0.09 0.474 0.676 0.011 (1.1° Week 12 1.039±0.11 1.00±0.10 0.560 P* value 0.515 0.710 T score Femoral neck Baseline -0.618±0.41 -0.187±0.97 0.205 0.785 0.005 (0.5°					•	,
T score Total whole body Baseline -0.918±0.80 -0.960±0.60 0.895 0.231 0.079 (7.99 Week 12 -0.909±0.90 -1.200±0.92 .0475 P* value 0.884 0.247 T score Total lumbar vertebral (L1-L4) Baseline 1.045±0.10 1.012±0.09 0.474 0.676 0.011 (1.19 Week 12 1.039±0.11 1.00±0.10 0.560 P* value 0.515 0.710 T score Femoral neck Baseline -0.618±0.41 -0.187±0.97 0.205 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0.59 0.785 0.005 (0						
Baseline -0.918±0.80 -0.960±0.60 0.895 0.231 0.079 (7.99) Week 12 -0.909±0.90 -1.200±0.92 .0475 P* value 0.884 0.247 T score Total lumbar vertebral (L1-L4) 8aseline 1.045±0.10 1.012±0.09 0.474 0.676 0.011 (1.19) Week 12 1.039±0.11 1.00±0.10 0.560 0.560 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.71		l whole body				
P° value 0.884 0.247 T score Total lumbar vertebral (L1-L4) Baseline 1.045±0.10 1.012±0.09 0.474 0.676 0.011 (1.19) Week 12 1.039±0.11 1.00±0.10 0.560 0.560 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 0.710 <th></th> <th></th> <th>-0.960±0.60</th> <th>0.895</th> <th>0.231</th> <th>0.079 (7.9%)</th>			-0.960±0.60	0.895	0.231	0.079 (7.9%)
T score Total lumbar vertebral (L1-L4)	Week 12	-0.909±0.90	-1.200±0.92	.0475	-	
Baseline 1.045±0.10 1.012±0.09 0.474 0.676 0.011 (1.19) Week 12 1.039±0.11 1.00±0.10 0.560 0.560 P° value 0.515 0.710 0.710 0.710 T score Femoral neck 0.618±0.41 -0.187±0.97 0.205 0.785 0.005 (0.59)	Pª value	0.884	0.247			
Baseline 1.045±0.10 1.012±0.09 0.474 0.676 0.011 (1.19) Week 12 1.039±0.11 1.00±0.10 0.560 0.560 P° value 0.515 0.710 0.710 0.710 T score Femoral neck 0.618±0.41 -0.187±0.97 0.205 0.785 0.005 (0.59)	T score Tota	l lumbar vertebral (L1-L4)				
P° value 0.515 0.710 T score Femoral neck Baseline -0.618±0.41 -0.187±0.97 0.205 0.785 0.005 (0.50)			1.012±0.09	0.474	0.676	0.011 (1.1%)
T score Femoral neck Baseline -0.618±0.41 -0.187±0.97 0.205 0.785 0.005 (0.50)	Week 12	1.039±0.11	1.00±0.10	0.560	•	
Baseline -0.618±0.41 -0.187±0.97 0.205 0.785 0.005 (0.5	Pª value	0.515	0.710			
	T score Fem	oral neck				
Week 120.618+0.260.175±0.990.321	Baseline	-0.618±0.41	-0.187±0.97	0.205	0.785	0.005 (0.5%)
	Week 12	-0.618±0.26	-0.175±0.88	0.321		
P ^a value 0.676 0.644	Pª value	0.676	0.644			

Note. EX=Exercise group; C= Control group; VO2max= Maximal oxygen uptake. Values are mean±SD; *Pa< 0.05, significantly different from baseline values by paired samples t-test (within groups, baseline vs. week 12). †Pb< 0.05, significantly different baseline and also week 12 values by independent samples t-test (between groups, baseline EX vs. baseline C; and week12 EX vs. week 12 C). ‡Pc< 0.05, significantly different between groups during the time (interaction) analyzed by univariate analysis of variance. Eta= Partial Eta squared or estimates of effect size.

et al., 2013). All human volunteers as participants attended the exercise venue and received information about the protocols and procedures, as well as the possible risks and benefits involved in the study. Informed written consent was obtained from all the human volunteers as participants. The human volunteers as participants (PMWs) were then randomly assigned to the EX (n=12) or C (n=12) groups by true random number generation (Table 1).

Dietary assessment

Dietary data was assessed via a 3-day food record (Bailey et al., 2009) in the first and last weeks of the exercise program (over 2 weekdays and 1 weekend day). The human volunteers as participants were requested to maintain their normal diet during the period of study and were instructed to consume a diet as similar as possible in each sampling day. Information on the use of medications/supplements was also obtained through standard and self-reported questionnaires (Bailey et al., 2009). Nutrition and dietary data were analyzed by nutrition analysis software (Nutrition data proTM v1.1, StarApps Company, USA) (Table 2).

Aerobic exercise program

Prior to the beginning of the study, each human volunteer as participant underwent a graded exercise treadmill test (GXT-Turbo Fitness, LX740, Taiwan) to determine the maximal oxygen uptake (VO2max). By using the Borg scale, rating of perceived exertion (RPE) was recorded in the last 10 s of each stage. Two of the following four criteria were required for a test to be considered maximal: (1) a plateau in VO2 despite increasing workload; (2) respiratory exchange ratio (RER)≥1.10; (3) maximal heart rate within 10 beats of age predicted max [HR_{max} = (208- (0.7×age in year)]; and (4) RPE≥17. The EX group participated in 12 weeks W-WJMIAEP-R on treadmill, 50 to 60 min/day, 3 days/week (180-200 min in week) at 65%-70% of each individual's maximal heart rate reserve (HR_{max}). In the first week of the study, the EX group performed W-WJMIAEP-R at 50% of each participant's HR_{max}. During the second and third weeks, the training intensity was increased to 60% of HR_{max} and then was progressed to 65%HRmax in the fourth to seventh weeks. In the last 5 weeks, human volunteers as participants were trained at 70% HR_{max}. Each training session included 10 min of prior warmup and 5 min of cooling down (active-recovery) at the ambient temperature of 22-25oC and relative humidity of 44%. All exercise sessions were performed between 08:00 and 10:00 AM and participants were supervised by trained physical education teachers. The C group participated in no intervention and continued their normal sedentary lifestyle, current physical activity level and dietary habits during 12 weeks.

Measurements

Physiological characteristics

Physiological characteristics of participants including age, menopause age and height, weight, and body mass index (BMI) were measured by ID card, self-reported menstrual history, wall-meter (Beurer, Germany), digital scale machine (Beurer, Germany), and weight/height2 formula, respectively. Total body fat was measured by Dual-energy X-ray absorptiometry (DXA) (Hologic, USA). Diastolic and systolic blood pressure and heart rate were measured by digital blood pressure monitor (WDF-BP001, Brisk, Germany). The physiological parameters were evaluated two times at baseline and week-12, except height values (Table 2).

Blood sampling and assays

Following a 12-hour overnight fasting, blood samples (10 ml) were taken in the early morning (between 07:00 and 08:00 AM) from a brachial vein of the left hand by Venoject needles in sitdown situation and relaxation. Blood samples (5 ml) were collected twenty-four hours before and after the 12-week training program in order to measure serum markers (ALP, PTH, Vit D, Ca2+, 17β -estradiol, and progesterone) in the EX and C groups. To separate serum levels, blood samples were centrifuged at a speed of 3000 rpm for 15 min at 4°C by centrifuge machine after 15 min clotting at chamber temperature. Serum PTH, Vit D, 17 β estradiol and progesterone measurements were assayed using an enzyme-linked immunosorbent assay (ELISA) kit (DiaSorin, USA), Bioactive Diagnostica (Homburg, Germany), (1561-DRG, Euroimmun, Germany), and (2633-DRG, Euroimmun, Germany), respectively. Serum levels were measured by ELISA device (Stat Fax®4200- Awareness Technology, USA). Serum ALP and Ca2+ levels were measured by standard automated laboratory techniques/BT-1500 machine. The other 5 ml remaining blood blood coated to an anticoagulant samples (total ethylenediaminetetra-acetic acid [EDTA]) were used to extract ribonucleic acid (RNA) in the expression of ALP and β -actin genes. The blood sample of gene expression stored at -70°C for 30 min, and then was quickly frozen in liquid nitrogen until subsequent analysis.

RNA extraction from peripheral blood lymphocytes (PBL) and complementary deoxyribnucleic- acid (cDNA) synthesis

After removing blood samples from the liquid nitrogen and defreezing them in the laboratory, the rapid genomic DNA extraction (RGDE) method was performed (Saremi, Saremi, & Tavallaei, 2008), and then RNA was extracted using the RNX-Plus RNA Extraction Kit (SinaClon, Iran) according to the manufacturer's instructions. The concentration and quality or purity of total RNA

was assessed on the basis of OD260/280 ratio (ng/µl) measurements using a NanoDrop 1000 Spectrophotometer (ThermoScientific, Wilmington, USA) and electrophoresis on a 1.2% agarose gel in 0.5 (ng/µl) ethidium bromides, respectively.

The RNA samples were converted to cDNA after treating with DNase I to eliminate any genomic DNA contamination. RNA reverse transcription (RT) was performed in a final volume of 20 (μ I) reaction mixtures containing 1 (μ I) template RNA, 1 (μ I) dN6 primer, and 18 (μ I) DEPC-DNase water by AccuPower® RocketScriptTM RT-PreMix cDNA kit (k-2101, Bioneer, Germany). According to the manufacturer's protocol, the reactions on the samples were performed by real time PCR (E750, ThermoScientific, Belgium). The synthesized cDNA samples were immediately stored at -70 0C for using expression of ALP and β -actin genes.

Primer design

Specific primers of ALP and β -actin (as a housekeeping/reference gene) genes were designed using GenScript online primer software and were checked by primer Blast and OligoAnalyzer idt tools. Then, for the preparation of primers, their lyophilized powders were prepared by Bioneer Company, Daejeon from South Korea. The sequences of primers for genes are shown in Table 3.

Quantitative real-time reverse transcription polymerase chain reaction (gRT-PCR) assay

To measure ALP and β -actin genes from qRT-PCR device (Applied BioSystem A, Step OneTM, USA), the manufacturer's protocols were applied. The reactions were performed on the basis of Syber Green-I (Maxima SYBR-Green/ROX gPCR MasterMix k-0221, ThermoScientific, Germany) with melting curve for both groups in the range of 60 to 95°C to evaluate the specific sequences of β -actin gene and ALP gene along with their temperature cycles. The protocols of ALP and β -actin genes for gRT-PCR reaction were as follows, respectively: initial denaturation at 95°C for 5 min (Holding step), followed by 40 cycles of denaturation at 95°C for 10 seconds (Denaturation step), annealing at 61°C for 10 seconds (Annealing step), and extension at 72°C for 20 seconds (Extension step). Initial denaturation at 95°C for 5 min (Holding step), followed by 40 cycles of denaturation at 95°C for 10 seconds (Denaturation step), annealing at 60°C for 15 seconds (Annealing step), and extension at 72°C for 20 seconds (Extension step). The reaction was carried out in a final volume of 12 μ l based on the desired amounts. To ensure for presence of DNA in the products of the gRT-PCR device, electrophoresis on a 1.2% agarose gel in 0.5 (ng/µl) ethidium bromides was applied. Finally, the mean of thres-hold cycle (CT) data was calculated by the 2- $^{\Delta\Delta c\tau}$ method (Livak & Schmittgen, 2001).

BMD and T score measurements

BMD measurements (g/cm2) were evaluated at the whole body, anterior-posterior lumbar vertebral (L1-L4) and the non-dominant proximal femur, including femoral neck, using DXA. T scores for the whole body, lumbar vertebral and the femoral neck were also calculated.

Statistical analysis

All data were expressed as means±standard deviation (SD) and checked for normality using Kolmogorov-Smirnov and homogenize of variances (Levene's test). Between-group differences were determined by independent samples t-test for baseline or week 12 values in the two groups. In addition, univariate analysis of variance (ANCOVA) test in a general linear model was applied to determine the changes of all variables between the two groups during the time (group-time interaction). The difference between baseline- and week 12 values for each group was investigated using paired samples t-test. To determine the correlations between BMD of the whole body, lumbar vertebral, femoral neck and other variables among PMWs at baseline and week 12, Pearson's correlation coefficient was applied. The statistical software program SPSS (SPSS Co, Chicago IL, version 23) for windows were used for data analysis. Statistical significance was considered at a P<0.05 of two-tailed for all tests. It should be noted that the sample size was calculated using G*Power software for ANCOVA-fixed and main effects and interactions for detecting a medium effect size (Cohen d ¼ 0.4) with an alpha of 0.05 and power of 95%. The total sample size was calculated as 24 participants.

Results

Baseline characteristics of participants did not show any significant differences between groups in physiological characteristics, menopause status, and bone parameters (p>0.05, Table 1). At the end of 12 weeks of aerobic exercise intervention, total body fat percentage (TBF) decreased significantly while VO2max, walking-jogging time to exhaustion (WJTE), and physical activity level or metabolic equivalent of task (METs) increased significantly in the EX group (p<0.05, Table 1). 17β-estradiol and progesterone decreased Moreover, significantly in the C group. The significant group-time interactions showed that the EX group compared with C group experienced significantly higher reduction in TBF (p=0.028), higher increase in the WJTE (p=0.001) and higher increase in the METs (p=0.001) as well as higher increase in the VO_{2max} (p=0.001) (Table 1). Dietary intake status in total energy intake

Table 2. Differences in dietary intake for PMWs at baseline and week 12 in the EX and C groups.

Variables	EX (n=12)	C (n=12)	P⁵ value	P° value
Total energy in	ntake (kcal/d)			
Baseline	2242.88±546.82	2366.12±515.60	0.602	0.341
Week 12	2303.36±335.22	2297.25±312.63	0.966	
Pª value	0.557	0.419		
Fat (g)				
Baseline	103.11±29.13	104.22±32.18	0.935	0.646
Week 12	103.14±26.04	100.29±21.14	0.787	
P ^a value	0.997	0.566		
Carbohydrate	(CHO) (g)			
Baseline	252.20±114.00	293.97±78.48	0.345	0.389
Week 12	264.74±85.26	282.18±63.76	0.605	
Pª value	0.436	0.200		
Protein (g)				
Baseline	88.75±23.28	77.96±26.58	0.334	0.470
Week 12	90.06±20.39	79.07±21.33	0.243	•
Pª value	0.693	0.656		

Note. EX= Exercise group; C= Control group; TEI= Total energy intake; Values are mean±SD. *Pa< 0.05, significantly different from baseline values by paired samples t-test (within groups, baseline vs. week 12). †Pb< 0.05, significantly different baseline and also week 12 values by independent samples t-test (between groups, baseline EX vs. baseline C; and week12 EX vs. week 12 C). ‡Pc< 0.05, significantly different between groups during the time (interaction) analyzed by univariate analysis of variance (between groups, baseline and week 12 EX vs. baseline and week 12 C).

(TEI), fat, carbohydrate (CHO), and protein did not show any significant within/between group differences among PMWs (p>0.05, Table 2). The two groups were similar regarding food intake at the beginning and at the end of 12 weeks of the study, and no change was occurred in food intake over time.

As illustrated in Table 4, the mean changes of ALP gene expression and serum ALP increased significantly during the time in the EX group compared to the C group, respectively (p=0.008 and p=0.001). Serum PTH increased significantly in the EX group

Table 3. Sequences of primers of ALP & β-actin genes for qRT-PCR.

Genes	and	Primer	Sequence of primers (5 → 3)	Product
Oligonucleotide		length		
Alkaline				
phosphatas	e (ALP)			
Forward prin	mer	20	TGAGAGTGACGAGAAAGCCA	92
Reverse pri	mer	20	GGGAGTGCTTGTATCTCGGT	_
β-actin				
Forward prin	mer	20	TGGACTTCGAGCAAGAGATG	137
Reverse pri	mer	20	GAAGGAAGGCTGGAAGAGTG	_

Note. qRT-PCR= Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction.

(p=0.031) while it showed a significant decrease in the C group (p=0.023). The PTH change during the time was significantly different between the two groups (p=0.001). Vit D showed significant increase in the EX group (p=0.001) while remained unchanged in the C group (p=0.307). Also, the change in Vit D during the time was significantly different between the groups (p=0.002). Serum Ca2+ did not change in the EX (p=0.953) or C (p=0.809) groups. There was no significant difference between the two groups regarding these changes during the time (p=0.990). The effect size (Eta) coefficient showed 22.8%, 53.4%, 55.1%, 97.9% 43.1%, 86.7%, 44.9% and 57.9% increase in TBF, VO2max, WJTE, METs, ALP gene expression, serum ALP, serum PTH and serum Vit D respectively in the EX group compared to the C group, whereas the other factors did not show considerable changes.

Discussion

The present study demonstrated that increase in the lymphocyte ALP gene expression was associated with normal BMD based on the T score values. The new findings of this study are: (1) 12 weeks of aerobic exercise improved cardiorespiratory fitness (CRF) through positive adaptations in physiological indices, including increase in the VO_{2max} , WJTE, and METs and decrease

in TBF among PMWs; (2) Normal T score values were maintained in healthy sedentary PMWs after 12 weeks of moderate-intensity aerobic exercise intervention while 3 PMWs (1 PMW at the lumbar vertebral and 2 PMWs at the femoral neck; 25%) experienced aging-induced osteopenia due to physically inactive in the C group; (3) Significant decrease was observed in serum levels of 17β -estradiol and progesterone after week 12 due to a rapid decline in sex hormones during menopause in the C group; (4) 12 weeks of aerobic exercise increased lymphocyte ALP gene expression in PMWs; (5) 12 weeks of moderate-intensity aerobic exercise intervention increased circulating level of PTH in PMWs; (6) 12 weeks of moderate-intensity aerobic exercise intervention increased the circulating levels of ALP and Vit D in PMWs; and these findings clearly show that the increases of ALP mRNA and circulating levels of PTH, ALP and Vit D with the promotion of CRF provides numerous benefits for bone turnover. To our knowledge, our study is the first to concurrently investigate the impact of moderate-intensity aerobic exercise on BMD, lymphocyte ALP gene expression, and biochemical markers of bone turnover including serum levels of PTH, ALP, Vit D, 17β estradiol and progesterone among PMWs.

Recent studies have reported that increase in CRF such as WJTE, VO2max and METs is associated with reduced risk factor

Table 4. ALP Gene expression, serum levels, BMD and T scores among PMWs at baseline and week 12 in the EX and C groups.

Variables	EX (n=12)	C (n=12)	P ^b value	P° value	Eta coefficient (%)
ALP gene expr	ession (fold change)				
Baseline	1.63±2.61	1.00±0.00	0.475	*0.008	0.431 (43.1%)
Week 12	2.80±2.96	0.42±0.34	*0.030		
Pª value	0.551	*0.001			
ALP serum (dl/	mg)				
Baseline	125.18±34.70	134.90±33.97	0.514	*0.001	0.867 (86.7%)
Week 12	217.27±56.83	136.55±30.96	*0.001	•	
Pª value	*0.001	0.419			
PTH serum (mi	l/ng)				
Baseline	31.42±13.71	32.74±13.89	0.825	*0.001	0.449 (44.9%)
Week 12	42.11±14.58	19.89±15.14	*0.002		
Pª value	*0.031	*0.023			
Vit D serum (m	l/ng)				
Baseline	3.99±1.62	5.30±3.03	0.291	*0.002	0.579 (57.9%)
Week 12	11.41±3.34	3.67±0.84	*0.001	•	
Pª value	*0.001	0.307			
Ca2+ serum (dl/	/mg)				
Baseline	9.43±0.35	9.28±0.28	0.105	0.990	0.001 (0.1%)
Week 12	9.42±0.45	9.38±0.91	0.988	•	
Pª value	0.953	0.809			

Note. EX= Exercise group; C= Control group; Values are mean±SD. *Pa< 0.05, significantly different from baseline values by paired samples t-test (within groups, baseline vs. week 12). †Pb< 0.05, significantly different baseline and also week 12 values by independent samples t-test (between groups, baseline EX vs. baseline C; and week12 EX vs. week 12 C). ‡Pc< 0.05, significantly different group - time interaction analyzed by univariate analysis of variance (between groups, baseline and week 12 EX vs. baseline and week 12 C). Eta= Partial Eta squared or estimates of effect size.

of osteopenia and/or osteoporosis in PMWs (DeFina et al., 2016). Furthermore, increased CRF is associated with lower all-cause and cardiovascular mortality (Tartibian, Botelho Teixeira, & Baghaiee, 2015) which can promote healthy cognitive and psychosocial function among PMWs (McKinney et al., 2016). It seems that increased CRF and decreased TBF lead to a reduction in sarcopenia indices such as aging-induced osteopenia (Lee et al., 2016) and obesity sarcopenia (Fukuda et al., 2018) in the EX group compared to the C group. In other words, it is possible that increased efficiency of cardiorespiratory system (CRS) and healthy skeletal system can delay aging-induced risk factors such as osteopenia, osteoporosis, and sarcopenia in menopause although the mechanism is unclear (McKinney et al., 2016). Also, our study showed that the ground reaction force (GRF) caused by 12 weeks W-WJMIAEP-R on treadmill did not provide the necessary pressure to stimulate BMD at three areas in the EX group; although, T score values remained normal. On the other hand, it is possible that aging-induced physically inactive and rapid reduction of sex hormones such as 17β -estradiol and progesterone in the first 1-5 years of menopause (Boonen et al., 2008) will facilitate the aging process and aging-induced disease such as osteopenia or osteoporosis, as 3 osteopenic PMWs (25%) were observed after 12 weeks in the C group.

It seems that increased ALP gene expression modulates osteoblast cells after 12 weeks of aerobic exercise in PMWs. It exerted mechanical stress into the biochemical cellular signaling of osteoblasts (Tartibian, Hajizadeh Maleki, Kanaley, & Sadeghi, 2011), thus, based on the hypothesis of mechanical stress, it is likely to increase calcium phosphate/hydroxyapatite and/or maintain normal BMD values at three areas in PMWs. Since osteoblast cells can be considered as a major source of ALP (Edwards, 2017; Goseki-Sone et al., 2005; Tartibian, Hajizadeh Maleki, Kanaley, & Sadeghi, 2011), increasing the ALP gene expression as well as its serum levels is a sign of stimulation in osteoblast cells (Goseki-Sone et al., 2005; Nabipour et al., 2008), and as a result, cellular signaling will increase with increasing BMD (Goseki-Sone et al., 2005; Nabipour et al., 2008). The ALP gene-induced changes have been reported to be important determinants of age-related bone loss, and the phosphate metabolism pathway is considered as a new purpose in preventing osteoporosis (Sharma, Pal, & Prasad, 2014). Also, since Akt signaling is required in all phases of osteoblast differentiation and is essential for osteogenesis and mineralization (Mukherjee & Rotwein, 2009), it is possible that activation of Akt signaling pathway is required for ALP-induced osteoblast differentiation and mineralization process in PMWs. On the other hand, elevation of ALP gene expression was associated with elevated serum ALP in the EX group, which is related to the bone mineralization process due to the role of serum ALP as a marker for osteogenic activity in hard tissue formation and bone metaboli-sm (Nabipour et al., 2008). Besides, another control of the ALP gene expression is applied through the action of Vit D (Maehata et al., 2006; Paredes et al., 2004), PTH (Wang et al., 2006), and retinoic acid (mediating ALP gene expression through unique pathways) and interaction with important regulatory systems (Maehata et al., 2006; Paredes et al., 2004; Rev et al., 2007; Wang et al., 2006). Furthermore, in the present study, there was a significant difference for serum PTH in between-groups, as it showed an increase in the EX group and decrease in the C group. Since osteoblast cells have PTH receptors (Yavropoulou, Michopoulos, & Yovos, 2017), it is likely that increased ALP gene expression stimulates PTH receptors and also increases the circulating levels of PTH, which is probably due to activation of PTH receptors which is probably due to the surface of osteoblasts and osteocytes (Datta & Abou-Samra, 2009). Also, elevated PTH serum is associated with increased bone formation and/or the life span and number of osteoblasts by prevention of osteoblast apoptosis (Jilka et al., 1999). Recent studies demonstrated a possible role for Wnt signaling pathway on PTH actions in bone metabolism (Yavropoulou, Michopoulos, & Yovos, 2017). On the other hand, it is possible that the activation of osteoblast cells by increased ALP gene expression is associated with elevated PTH serum as well as elevated ALP serum after 12 weeks of aerobic exercise in the EX group. However, according to the findings of previous studies, the PTH duality effects on increasing and/or decreasing bone formation remain unclear (Rey et al., 2007; Yavropoulou, Michopoulos, & Yovos, 2017); therefore, increasing or decreasing this hormone by aerobic exercise depends on several factors, such as intensity, duration, and the level of exercise (Tartibian, Hajizadeh Maleki, Kanaley, & Sadeghi, 2011). Moreover, insufficient serum levels of Vit D with decreased serum PTH are associated with risk factors of bone resorption or osteoporosis and mortality (Cerdá Gabaroi et la., 2010; Tartibian, Hajizadeh Maleki, Kanaley, & Sadeghi, 2011), as observed in the C group of our study. Recent evidences indicate that Vit D plays an important role in the aging process (Berridge, 2016). The ability of Vit D synthesizes by human skin declines with aging process (Berridge, 2016). Also, dysregulation of the Ca2+ signaling and mitochondrial dysfunction are associated with aging process (Decuypere et al., 2011). Furthermore, Vit D acts by maintaining the totality of cell signaling pathways such as Ca2+ and reactive oxygen species (ROS) signaling pathways (Berridge, 2016). It is possible that decreased Vit D levels result in an increase in the activation of Ca2+ and ROS signaling pathways (Berridge, 2016) that not only lead to accelerate the process of aging, but also facilitate the aging process-related diseases such as osteopenia and/or osteoporosis and consequently increases a high risk of mortality in PMWs (Cerdá Gabaroi et la., 2010). In contrast, elevated serum levels of Vit D are associated with osteoblast differentiation and bone formation (VanDriel & VanLeeuwen, 2014). In other words, since osteoblast cells have Vit D receptors

(Peppel & VanLeeuwen, 2014; VanDriel & VanLeeuwen, 2014; Wang, Zhu, DeLuca, 2014), Vit D plays a direct role on osteoblasts whose magnitude is related to the presence of other hormones (such as PTH) (VanDriel & VanLeeuwen, 2014) and other signaling molecules (such as Wnt signaling) (Woeckel et al., 2013). Further, increasing Vit D has a stimulatory effect on ALP mRNA, protein synthesis, and activity of osteoblasts in humans and/or PMWs (VanDriel & VanLeeuwen, 2014). In addition, a recent study has reported that increased Vit D level is associated with improved CRF including VO2max in the women; although, the mechanism is unclear (Marawan, Kurbanova, & Qayyum, 2018; Marawan, Kurbanova, & Qayyum, 2019).

The findings of our study showed significant positive correlation between BMD whole body and ALP gene expression (P=0.034) in the EX group at week 12 while the significant negative correlation was observed between BMD and Progesterone (P=0.010) in the C group. ALP is an important marker for determining age-related changes in bone turnover (Zhou et al., 2013). Also, the results of studies revealed that increased ALP mRNA and Vit D. as well as elevated PTH increase bone turnover or BMD by increasing the life span and number of osteoblasts (Jilka et al., 1999; Zhou et al., 2013). It seems that 12 weeks of moderate-intensity aerobic exercise intervention exerts the mechanical stress on whole body, and as a result, ALP mRNA expression and serum ALP will increase with maintaining and/or increasing BMD whole body during menopause. In addition, significant positive correlation was observed between BMD lumbar vertebral and WJTE (P=0.001) in the EX group, which confirms the positive correlation between CRF and BMD in PMWs. The significant negative correlation was observed between BMD femoral neck and menopause age (P=0.037) in the EX group, whereas the correlations of other variables were not statistically significant. The studies have reported that due to a decline in sex hormones such as estrogen and progesterone levels in the first 5 years of menopause (Boonen et al., 2008), PMWs are four times more likely to develop aging-induced diseases such as osteopenia and osteoporosis (DeFina et al., 2016), and as a result, a rapid reduction in BMD occurs in the first 1-5 years immediately following menopause (Boonen et al., 2008) which was similar in the C group.

The current study had some limitations. We only measured ALP gene expression at the mRNA level, but not at the protein level. Also, the human volunteers as participants in our study were only healthy sedentary PMWs aged 50-60 years and consequently the findings of our study can't be generalized to the other statistical populations such as young women, girls, men, and boys.

Conclusion

The findings of present study showed that 12 weeks of moderate-intensity aerobic exercise intervention at 65%-70% HR_{max} increa-

-sed lymphocyte ALP gene expression and circulating levels of ALP and Vit D in PMWs, which was associated with CRF and numerous benefits of bone turnover. In contrast, it seems that inadequate Vit D levels, decreased PTH, and decreased estrogen and progesterone due to 12-week physically inactive lead to BMD loss during menopause, as PMWs (25%) experienced aging-induced osteopenia in the C group. In addition, it is possible that increasing in ALP mRNA is associated with elevated Vit D and PTH concentrations. These findings supply additional evidence to support the viewpoint that 12 weeks of moderate-intensity aerobic exercise intervention may have numerous benefits in bone formation such as increased ALP mRNA expression, increased Vit D serum, and increased PTH serum, as well as prevention of BMD loss in healthy sedentary PMWs aged 50-60 years.

What is already known on this subject?

Studies have examined the effects of exercise on serum markers of bone metabolism and BMD, but their results are completely contradictory.

What this study adds?

Twelve weeks of moderate-intensity aerobic exercise intervention improve bone turnover by increasing the ALP mRNA expression, serum levels of PTH, ALP, and Vit-D which can lead to the prevention of aging-induced osteopenia among PMWs.

Acknowledgements

The authors are grateful to the human volunteers who participated in this study. We also wish to thank Dr. Mohammad Pourhassan-Moghaddam (Associate Professor of Medical Biotechnology, Tabriz University of Medical Sciences, Iran) who designed the specific ALP primers for osteoblast cells in our study.

Funding

No funding.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval The all stages of this study were approved by the Ethics Committee of medical-biological sciences at Urmia University of medical sciences with code ir.umsu.rec.1394.453 and were conducted in September 2017 at Urmia University, Iran.

Informed consent Participants signed a written informed consent form that was approved by the ethical committee.

Author contributions

Conceptualization: A.M., Z.Sh.; Methodology: B.T., M.R-Y.; Software: A. M., Z. Sh.; Validation: B.T.; Formal analysis: M.R-Y.; Investigation: B.T., M.R-Y.; Resources: A.M.; Data curation: Z.Sh.; Writing - original draft: A.M., Z.Sh.; Writing - review & editing: B.T., M.R-Y.; Visualization: B.T., M.R-Y.; Supervision: A.M., Z.Sh.; Project administration: A.M.; Funding acquisition: Z.Sh.

References

Azadpour, N., Tartibian, B., & KoŞar, Ş.N. (2016) Effects of aerobic exercise training on ACE and ADRB2 gene expression, plasma angiotensin II level, and flow-mediated dilation: a study on obese postmenopausal women with prehypertension. Menopause, 24, 269-277. URL: https://pubmed.ncbi.nlm.nih.gov/28231078/

Bailey, R.L., Miller, P.E., Mitchell, D.C., Hartman, T.J., Lawrence, F.R., Sempos, C.T., & Smiciklas-Wright, H. (2009). Dietary screening tool identifies nutritional risk in older adults. The American Journal of Clinical Nutrition, 90, 177-83. PubMed doi: https://doi.org/10.3945/ajcn.2008.27268

Berridge, M.J. (2016). Vitamin D, reactive oxygen species and calcium signaling in ageing and disease. Philosophical Transactions of the Royal Society of London, Series B, Biological Sciences, 371, 20150434. PubMed doi: https://doi.org/10.1098/rstb.2015.0434

Boonen, S., Dejaeger, E., Vanderschueren, D., Venken, K., Bogaerts, A., Verschueren, S., & Milisen, K. (2008). Osteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective. Best Practice & Research Clinical Endocrinology & Metabolism, 22, 765-85. PubMed doi: https://doi.org/10.1016/j.beem.2008.07.002

Cauley, J.A., Danielson, M.E., Greendale, G.A., Finkelstein, J.S., Chang, Y.F., Lo, J.C., . . . Sowers, M.R. (2012). Bone resorption and fracture across the menopausal transition: The Study of Women's Health Across the Nation. Menopause, 19, 1200-1207. PubMed doi: https://doi.org/10.1097/gme.0b013e31825ae17e

Cerdá Gabaroi, D., Peris, P., Monegal, A., Albaladejo, C., Martínez, M.A., Muxí, A., . . . Guañabens N. (2010). Search for hidden secondary causes in postmenopausal women with osteoporosis. Menopause, 17, 135-9. PubMed doi: https://doi.org/10.1097/gme.0b013e3181ade8e5

Datta, N.S., & Abou-Samra, A.B. (2009). PTH and PTHrP signaling in osteoblasts. Cellular Signaling, 21, 1245-54. PubMed doi: https://doi.org/10.1016/j.cellsig.2009.02.012

Decuypere, J.P., Monaco, G., Missiaen, L., DeSmedt, H., Parys, J.B., & Bultynck, G. (2011) IP3 receptors, mitochondria, and Ca2+ signaling: implications for aging. Journal of Aging Research, 2011, 1-20. PubMed doi: https://doi.org/10.4061/2011/920178

DeFina, L.F., Leonard, D., Willis, B.L., Barlow, C.E., Finley, C.E., Jenk-

-ins, M.R., . . . Shen, C.L. (2016). High cardiorespiratory fitness is associated with reduced risk of low bone density in postmenopausal women. Journal of Women's Health (Larchmt), 25, 1073-1080. PubMed doi: https://doi.org/10.1089/jwh.2014.5170

Eastell, R., Rosen, C.J., Black, D.M., Cheung, A.M., Murad, M.H., & Shoback, D. (2019). Pharmacological management of osteoporosis in postmenopausal women: An endocrine society* clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 104, 1595–1622. PubMed doi: https://doi.org/10.1210/jc.2019-00221

Edwards, B.J. (2017). Osteoporosis risk calculators. Journal of Clinical Densitometry, 20, 379-388. PubMed doi: https://doi.org/10.1016/j.jocd.2017.06.024

Fukuda, T., Bouchi, R., Takeuchi, T., Tsujimoto, K., Minami, I., Yoshimoto, T., & Ogawa, Y. (2018). Sarcopenic obesity assessed using dual energy X-ray absorptiometry (DXA) can predict cardiovascular disease in patients with type 2 diabetes: a retrospective observational study. Cardiovascular Diabetology, 17, 55. PubMed doi: https://doi.org/10.1186/s12933-018-0700-5

Goseki-Sone, M., Sogabe, N., Fukushi-Irie, M., Mizoi, L., Orimo, H., Suzuki, T., . . . Hosoi, T. (2005). Functional analysis of the single nucleotide polymorphism (787T>C) in the tissue-nonspecific alkaline phosphatase gene associated with BMD. Journal of Bone and Mineral Research, 20, 773-82. PubMed doi: https://doi.org/10.1359/JBMR.041229

Jilka, R.L., Weinstein, R.S., Bellido, T., Roberson, P., Parfitt, A.M., & Manolagas, S.C. (1999). Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. Journal of Clinical Investigation, 104, 439-46. PubMed doi: https://doi.org/10.1172/JCI6610

Karinkanta, S. (2017) Exercise: a comprehensive tool for ageing women to take care of their health. Menopause, 24, 7-8. PubMed doi: https://doi.org/10.1097/GME.0000000000000099

Khalafi, M., Malandish, A., Rosenkranz, S.K (2021). The impact of exercise training on inflammatory markers in postmenopausal women: A systemic review and meta-analysis. Exp Gerontol, 150, 111398. doi: https://doi.org/10.1016/j.exger.2021.111398

Lee, I., Cho, J., Jin, Y., Ha, C., Kim, T., & Kang, H. (2016). Body fat and physical activity modulate the association between sarcopenia and osteoporosis in elderly korean women. Journal of Sports Science and Medicine, 15, 477-482. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974860/

Livak, K.J., & Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-8. PubMed doi: https://doi.org/10.1006/meth.2001.1262

Maehata, Y., Takamizawa, S., Ozawa, S., Kato, Y., Sato, S., Kubota, E., & Hata, R. (2006). Both direct and collagen-mediated signals are required for active vitamin D3-elicited differentiation of human osteobl-

-astic cells: roles of osterix, an osteoblast-related transcription factor. Matrix Biology, 25, 47-58. PubMed doi: https://doi.org/10.1016/j.matbio.2005.09.001

Marawan, A., Kurbanova, N., & Qayyum, R. (2018). Association between serum vitamin D levels (VD) and cardiorespiratory fitness in the adult population of the United States. Journal of the American College of Cardiology, 71, A1798. PubMed doi: https://doi.org/10.1016/S0735-1097(18)32339-8

Marawan, A., Kurbanova, N., & Qayyum, R. (2019). Association between serum vitamin D levels and cardiorespiratory fitness in the adult population of the USA. European Journal of Preventive Cardiology, 26, 750-755. PubMed doi: https://doi.org/10.1177/2047487318807279

Malandish, A., Tartibian, B., Rahmati, M., Afsargharehbagh, R., Sheikhlou, Z (2020a). The effect of moderate-intensity aerobic training on pulmonary function and estrogen receptor-alpha gene in postmenopausal women with vitamin D deficiency: A randomized control trial. Respir Physiol Neurobiol, 281, 103510. doi: https://doi.org/10.1016/j.resp.2020.103510

Malandish, A., Tartibian, B., Rahmati Yamchi, M. (2016). Effect of 12 Weeks of Moderate-Intensity Aerobic Training on Bone Density and Serum Indices of Bone in Sedentary Postmenopausal Women. Sport Physiol, 8(32), 67-84. doi: https://doi.org/10.22089/spj.2016.862

Malandish, A., Tartibian, B., Sheikhlou, Z., Afsargharehbagh, R., Rahmati, M (2020b). The effects of short-term moderate intensity aerobic exercise and long-term detraining on electrocardiogram indices and cardiac biomarkers in postmenopausal women. J Electrocardiol, 60, 15-22. doi: https://doi.org/10.1016/j.jelectrocard.2020.03.004

McKinney, J., Lithwick, D.J., Morrison, B.N., Nazzari, H., Isserow, S.H., Heilbron, B., & Krahn, A. (2016). The health benefits of physical activity and cardiorespiratory fitness. BCMedical Journal, 58, 131-137. URL: https://bcmj.org/articles/health-benefits-physical-activity-and-cardiorespiratory-fitness

Mukherjee, A., & Rotwein, P. (2009). Akt promotes BMP2-mediated osteoblast differentiation and bone development. Journal of Cell Science, 122, 716-26. PubMed doi: https://doi.org/10.1242/jcs.042770

Nabipour, I., Larijani, B., Beigi, S., Jafari, S.M., Amiri, M., Assadi, M., . . . Sanjdideh Z. (2008). Relationship among insulinlike growth factor I concentrations, bone mineral density, and biochemical markers of bone turnover in postmenopausal women: a population-based study. Menopause, 15, 934-9. PubMed doi: https://doi.org/10.1097/gme.0b013e31816665a7

Paredes R, Arriagada G, Cruzat F, Villagra A, Olate J, Zaidi K, . . . Montecino M. (2004). Bone-specific transcription factor Runx2 interacts with the 1alpha,25-dihydroxyvitamin D3 receptor to up-regulate rat osteocalcin gene expression in osteoblastic cells. Molecular and Cellular Biology, 42, 8847-61. PubMed doi: https://doi.org/10.1128/MCB.24.20.8847-8861.2004

Peppel, J.v., & van Leeuwen, J. (2014). Vitamin D and gene networks

in human osteoblasts. Frontiers in Physiology, 5, 137. PubMed doi: https://doi.org/10.3389/fphys.2014.00137

Rey, A., Manen, D., Rizzoli, R., Ferrari, S.L., & Caverzasio, J. (2007). Evidences for a role of p38 MAP kinase in the stimulation of alkaline phosphatase and matrix mineralization induced by parathyroid hormone in osteoblastic cells. Bone, 41, 59-67. PubMed doi: https://doi.org/10.1016/j.bone.2007.02.031

Saremi, M.A., Saremi, M., & Tavallaei, M. (2008). Rapid genomic DNA extraction (RGDE). Forensic Science International: Genetics Supplement Series, 1, 63-65. PubMed doi: https://doi.org/10.1016/j.fsigss.2007.12.001

Sharma, U., Pal, D., & Prasad, R. (2014). Alkaline Phosphatase: An overview. Indian Journal of Clinical Biochemistry, 29, 269-278. PubMed doi: https://doi.org/10.1007/s12291-013-0408-y

Sheikhlou, Z., Tartibian, B., Malandish, A (2016). Effect of 12 weeks of moderate-intensity aerobic exercise (W-WJMIEP-R) on serum levels of vitamin D, parathyroid hormone, calcium, and phosphorous in overweight postmenopausal women. J Sport in Biomotor Sci, 8(15), 27-36. doi: https://doi.org/10.22080/JAEP.2017.8618.1405

Stewart, T.L., & Ralston, S.H. (2000). Role of genetic factors in the pathogenesis of osteoporosis. Journal of Endocrinology, 166, 235-245. PubMed doi: https://doi.org/10.1677/joe.0.1660235

Strath, S.J., Kaminsky, L.A., Ainsworth, B.E., Ekelund, U., Freedson, P.S., Gary, R.A., . . . Swartz, A.M. (2013). Guide to the assessment of physical activity: Clinical and research applications: a scientific statement from the American Heart Association. Circulation, 128, 2259-79. doi: https://doi.org/10.1161/01.cir.0000435708.67487

Tartibian, B., Afsargharehbagh, R., Malandish, A., Sheikhlou, Z (2018a). Assessment of electrocardiogram indices in postmenopausal women: effects of aerobic exercise and detraining. Int J Basic Sci Med, 3(1), 38-45. doi: https://doi.org/10.15171/ljjbsm.2018.07

Tartibian, B., Botelho Teixeira, AM., & Baghaiee, B. (2015). Moderate intensity exercise is associated with decreased angiotensin-converting enzyme, increased $\beta 2$ -adrenergic receptor gene expression, and lower blood pressure in middle-aged men. Journal of Aging and Physical Activity, 23, 212-220. PubMed doi: https://doi.org/10.1123/japa.2013-0136

Tartibian, B., Hajizadeh Maleki, B., Kanaley, J., & Sadeghi, K. (2011) Long-term aerobic exercise and omega-3 supplementation modulate osteoporosis through inflammatory mechanisms in post-menopausal women: a randomized, repeated measures study. Nutrition & Metabolism (London), 15, 71. PubMed doi: https://doi.org/10.1186/1743-7075-8-71

Tartibian, B., Malandish, A., Afsargharehbagh, R., Eslami, R., Sheikhlou, Z (2018b). Assessment of Hepatic and Lipid Profiles Following 12 Weeks of Aerobic Exercise in Overweight Postmenopausal Women. Int J Basic Sci Med, 3(1), 38-45. doi: https://doi.org/10.15171/ijbsm.2018.28

VanDriel, M., & VanLeeuwen, J.P. (2014). Vitamin D endocrine system and osteoblasts. BoneKEy Reports, 3, 493. PubMed doi: https://doi.org/10.1038/bonekey.2013.227

Wang, B.L., Dai, C.L., Quan, J.X., Zhu, Z.F., Zheng, F., Zhang, H.X., . . . Qiu, M.C. (2006). Parathyroid hormone regulates osterix and Runx2 mRNA expression predominantly through protein kinase A signaling in osteoblast-like cells. Journal of Endocrinological Investigation, 29, 101-8. PubMed doi: https://doi.org/10.1007/BF03344081

Wang, Y., Zhu, J., & DeLuca, H.F. (2014). Identification of the vitamin D receptor in osteoblasts and chondrocytes but not osteoclasts in mouse bone. Journal of Bone and Mineral Research, 29, 685-92. PubMed doi: https://doi.org/10.1002/jbmr.2081

Woeckel, V.J., Bruedigam, C., Koedam, M., Chiba, H., van der Eerden, B.C., & van Leeuwen, J,P. (2013).1α,25-dihydroxyvitamin D3 and rosiglitazone synergistically enhance osteoblast-mediated mineralization. Gene, 512, 438-43. doi: https://doi.org/10.1016/j.gene.2012.07.051

Yavropoulou, M.P., Michopoulos, A., & Yovos, J.G. (2017). PTH and PTHR1 in osteocytes. New insights into old partners. Hormones (Athens), 16, 150-160. PubMed doi: https://doi.org/10.14310/horm.2002.1730

Yu, P.A., Hsu, W.H., Hsu, W.B., Kuo, L.T., Lin, Z.R., Shen, W.J., & Hsu, R.W. (2019). The effects of high impact exercise intervention on bone mineral density, physical fitness, and quality of life in postmenopausal women with osteopenia: A retrospective cohort study. Medicine (Baltimore), 98, e14898. PubMed doi: https://doi.org/10.1097/MD.0000000000014898

Zhou, S., Glowacki, J., Kim, S.W., Hahne, J., Geng, S., Mueller, S.M., . . . LeBoff, M.S. (2013). Clinical characteristics influence in vitro action of 1,25-Dihydroxyvitamin D3 in human marrow stromal cells. Journal of Bone and Mineral Research, 27, 1992–2000. PubMed doi: https://doi.org/10.1002/jbmr.1655